Table 2. Frequency of IL28B genotype, KIR3DL1/HLA-Bw4, and KIR2DL2/HLA-C1 combinations in 56 patients with a sustained virological response (SVR) and 59 patients with a non-SVR to pegylated interferon and ribavirin therapy of chronic hepatitis C.
| KIR3DL1/HLA-Bw4 | KIR2DL2/HLA-C1 | SVR | Non-SVR | P (Pc) | OR (95% CI) |
|---|---|---|---|---|---|
| (n = 56) | (n = 59) | ||||
| +/+ | +/+ | 5 (9%) | 7 (12%) | 0.61 | |
| +/+ | Other | 31 (55%) | 19 (32%) | 0.012 (0.1) | 2.61 (1.22 - 5.58) |
| Other | +/+ | 1 (2%) | 10 (17%) | 0.014 (0.12) | 0.09 (0.01 - 0.72) |
| Other | Other | 19 (34%) | 23 (39%) | 0.57 | |
| IL28B | KIR3DL1/HLA-Bw4 | SVR | Non-SVR | P (Pc) | OR (95% CI) |
| (n = 56) | (n = 59) | ||||
| TT | +/+ | 27 (48%) | 13 (22%) | 0.003 (0.024) | 3.29 (1.47 - 7.39) |
| TT | Other | 17 (30%) | 14 (24%) | 0.42 | |
| TG/GG | +/+ | 9 (16%) | 13 (22%) | 0.42 | |
| TG/GG | Other | 3 (5%) | 19 (32%) | 0.00062 (0.0005) | 0.12 (0.03 - 0.43) |
| IL28B | KIR2DL2/HLA-C1 | SVR | Non-SVR | P (Pc) | OR (95% CI) |
| (n = 56) | (n = 59) | ||||
| TT | Other | 38 (68%) | 18 (31%) | 0.000062 (0.0005) | 4.81 (2.19 - 10.58) |
| TT | +/+ | 6 (11%) | 9 (15%) | 0.47 | |
| TG/GG | Other | 12 (21%) | 24 (41%) | 0.026 (0.21) | 0.40 (0.17 - 0.91) |
| TG/GG | +/+ | 0 (0%) | 8 (14%) | 0.013 (0.1) | - |
Data are expressed as n (%).